Works Cited

1. Bashashati M, Hejazi RA, Andrews CN, Storr MA. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? Can J Gastroenterol Hepatol. 2014;28(6):335-341.

2. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112(7):988-1013.

3. Grossi L, Ciccaglione AF, Marzio L. Esophagitis and its causes: who is "guilty" when acid is found "not guilty"? World J Gastroenterol. 2017;23(17):3011-3016.

4. Antunes C, Curtis SA. Gastroesophageal Reflux Disease. Treasure Island, FL: StatPearls Publishing; 2017.

5. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262-1279.

6. Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-163.

7. Aziz Q, Fass R, Gyawali P, Miwa H, Pandolfino JE, Zerbib F. Esophageal disorders. Gastroenterology. 2016;150(6):1368-1379.

8. Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation Global Guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017;51(6):467-478.

9. Zentilin P, Marabotto E, Pellegatta G, et al. Complexity and diversity of GERD phenotypes. Minerva Gastroenterol Dietol. 2017;63(3):198-204.

10. Cleveland Clinic. GERD (Chronic Acid Reflux). Available at https://my.clevelandclinic.org/health/diseases/17019-gerd-or-acid-reflux-or-heartburn-overview. Last accessed September 7, 2021.

11. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880.

12. Hershcovici T, Fass R. Nonerosive reflux disease (NERD): an update. J Neurogastroenterol Motil. 2010;16(1):8-21.

13. Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther. 2007; 26(3):453-461.

14. Vakil N, Stelwagon M, Shea EP, Miller S. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United European Gastroenterol J. 2015;4(3):413-422.

15. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328.

16. Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet needs in the treatment of gastroesophageal reflux disease.J Neurogastroenterol Motil. 2015;21(3):309-319.

17. Jaspersen D, Kulig M, Labenz J, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther. 2003;17(12):1515-1520.

18. Lee JS. The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med. 2014;21(2):81-85.

19. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101(11):2646-2654.

20. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116(2):254-260.

21. Havas T, Huang S, Levy M. Posterior pharyngolaryngitis: double-blind randomized placebo-controlled trial of proton pump inhibitor therapy. Aust J Otolaryngol. 1999;3:243-246.

22. Wong WM, Fass R. Extraesophageal and atypical manifestations of GERD. J Gastroenterol Hepatol. 2004;19(Suppl 3):S33-S43.

23. Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting—a population-based study. Aliment Pharmacol Ther. 2003;17(9):1115-1124.

24. Sontag SJ. The spectrum of pulmonary symptoms due to gastroesophageal reflux. Thorac Surg Clin. 2005;15(3):353-368.

25. Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999;116(5):1257-1264.

26. Chipps BE, Haselkorn T, Paknis B, et al. More than a decade follow-up in patients with severe or difficult-to-treat asthma. The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II. J Allergy Clin Immunol. 2017;6749(17)31270-1278.

27. Jaspersen D, Nocon M, Labenz J, et al. Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care: a 5-year follow-up. Aliment Pharmacol Ther. 2009;29(11):1172-1178.

28. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448-1456.

29. Fass R, Dickman R. Non-cardiac chest pain: an update. Neurogastroenterol Motil. 2006;18(6):408-417.

30. Fass R, Zerbib F, Gyawali CP. AGA clinical practice update on functional heartburn: expert review. Gastroenterology. 2020;158:2286-2293.

31. Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381:1513-1523.

32. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172-180.

33. de Bortoli N, Martinucci I, Savarino E, et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil. 2014;26(1):28-35.

34. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD): acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17(4):537-545.

35. Kushnir VM, Sayuk GS, Gyawali CP. The effect of antisecretory therapy and study duration on ambulatory esophageal pH monitoring. Dig Dis Sci. 2011;56(5):1412-1419.

36. Yamasaki T, Fass R. Reflux hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil. 2017;23:495-503.

37. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569-1580.

38. Kwan AC, Bao T, Chakkaphak S, et al. Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol. 2003;18(7):796-802.

39. Lin M, Gerson LB, Lascar R, Davila M, Triadafilopoulos G. Features of gastroesophageal reflux disease in women. Am J Gastroenterol. 2004;99(8):1442-1447.

40. Vega KJ, Langford-Legg T, Palacio C, Watts J, Jamal MM. Females without reflux symptoms or gastroesophageal reflux disease have less distal esophageal acid exposure than males without reflux symptoms or gastroesophageal reflux disease. Dis Esophagus. 2013;26(3):246-249.

41. Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2016;22(4):575-588.

42. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720-737.

43. Lundell L, Hatlebakk J, Galmiche JP, et al. Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial. Curr Med Res Opin. 2015;31(1):65-73.

44. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98(7):1487-1493.

45. Modlin IM, Moss SF. Symptom evaluation in gastroesophageal reflux disease. J Clin Gastroenterol. 2008;42(5):558-563.

46. Pearl J, Pauli E, Dunkin B, Stefanidis D, Society of American Gastrointestinal and Endoscopic Surgeons. Clinical Spotlight Review: Endoluminal Treatments for Gastroesophageal Reflux Disease (GERD). Available at https://www.sages.org/publications/guidelines/endoluminal-treatments-for-gastroesophageal-reflux-disease-gerd. Last accessed September 7, 2021.

47. Ajumobi AB, Vuong R, Ahaneku H. Analysis of nonformulary use of PPIs and excess drug cost in a Veterans Affairs population.J Manag Care Pharm. 2012;18(1):63-67.

48. Johansen ME, Huerta TR, Richardson CR. National use of proton pump inhibitors from 2007 to 2011. JAMA Intern Med. 2014;174(11):1856-1858.

49. Khieu M, Bhimji SS. Barrett Esophagus. Treasure Island, FL: StatPearls Publishing; 2017.

50. Zeid Y, Confer J. Standards of care for GERD. US Pharmacist. 2016;41(12):24-29.

51. Orlando RC, Paterson WG, Harnett KM, et al. Esophageal disease: updated information on inflammation. Ann N Y Acad Sci. 2011;1232:369-375.

52. Subramanian CR, Triadafilopoulos G. Refractory gastroesophageal reflux disease. Gastroenterology Report. 2015;3(1):41-53.

53. de Bortoli N, Penagini R, Savarino E, Marchi S. Eosinophilic esophagitis: update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE). Dig Liver Dis. 2017;49(3):254-260.

54. Moawad FJ, Molina-Infante J, Lucendo AJ, Cantrell SE, Tmanova L, Douglas KM. Endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96-105.

55. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230-1236.

56. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143(2):336-346.

57. Patti MG. Gastroesophageal Reflux Disease. Available at https://emedicine.medscape.com/article/176595-overview. Last accessed September 7, 2021.

58. Khan A, Kim A, Sanossian C, Francois F. Impact of obesity treatment on gastroesophageal reflux disease. World J Gastroenterol. 2016;22(4):1627-1638.

59. Triadafilopoulos G, Clarke JO, Hawn M. Precision GERD management for the 21st century. Dis Esophagus. 2017;30(9):1-6.

60. Patrick L. Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. Altern Med Rev. 2011;16(2):116-133.

61. Bozimowski G. A review of nonsteroidal anti-inflammatory drugs. AANA J. 2015;83(6):425-433.

62. Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases: a position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016;14(1):179.

63. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstron D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.Am J Gastroenterol. 2014;109(6):811-819.

64. Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(1):42-50.

65. Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19-32.

66. Oka Y, Okamoto K, Kawashita N, Shirakuni Y, Takagi T. Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. Biol Pharm Bull. 2014;37(6):947-953.

67. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-715.

68. Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14(6):809-815.

69. Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis: an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;13:55.

70. Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc. 2014;89(12):1699-1709.

71. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf. 2000;22(3):237-249.

72. Pimentel M, Rossi F, Chow EJ, et al. Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux.J Clin Gastroenterol. 2002;34(3):221-224.

73. Punjabi P, Hira A, Prasad S, Wang X, Chokhavatia S. Review of gastroesophageal reflux disease (GERD) in the diabetic patient.J Diabetes. 2015;7(5):599-609.

74. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study. Aliment Pharmacol Ther. 2013;37(3):323-331.

75. Ronkainen J, Talley NJ, Storskrubb T, et al. Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol. 2011;106(11):1946-1952.

76. Bredenoord AJ, Weusten BLAM, Sifrim D, Timmer R, Smout AJ. Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. Gut. 2004;53(11):1561-1565.

77. Vaezi MF, Pandolfino JE, Vela MF, Shaheen NJ. White paper AGA: optimal strategies to define and diagnose gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2017;15(8):1162-1172.

78. Dacha S, Razvi M, Massaad J, Cai Q, Wehbi M. Hypergastrinemia. Gastroenterol Rep. 2015;3(3):201-208.

79. Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol. 2017;33(6):430-438.

80. Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The gastric and intestinal microbiome: role of proton pump inhibitors.Curr Gastroenterol Rep. 2017;19(8):42.

81. Roman S, Holloway R, Keller J, et al. Validation of criteria for the definition of transient lower esophageal sphincter relaxations using high-resolution manometry. Neurogastroenterol Motil. 2017;29(2).

82. Cleveland Clinic. Peptic Ulcer Disease. Available at https://my.clevelandclinic.org/health/diseases/10350-peptic-ulcer-disease. Last accessed September 7, 2021.

83. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43(1):161-173.

84. Kahrilas PJ, McColl K, Fox M, et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol. 2013;108(7):1058-1064.

85. Souza RF. From reflux esophagitis to esophageal adenocarcinoma. Dig Dis. 2016;34(5):483-490.

86. McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34(2):146-165.

87. Tebala GD. Gastroesophageal reflux disease: are we acting in the best interest of our patients? Eur Rev Med Pharmacol Sci. 2016;20(21):4553-4556.

88. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation.Gut. 2006;55(3):313-318.

89. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354-1359.

90. Dunbar KB, Agoston AT, Odze RD, et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA. 2016;315(19):2104-2112.

91. Kim JJ, Kim N, Choi YJ, Kim JS, Jung HC. Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extraesophageal reflux symptoms. Medicine (Baltimore). 2016;95(32):e4387.

92. Holzer P. Acid sensing by visceral afferent neurones. Acta Physiologica (Oxf). 2011;201(1):63-75.

93. Ma J, Altomare A, Guarino M, et al. HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2012;303(5):G635-G645.

94. Choi YJ, Kim N, Kim JJ, Lee DH, Park JH, Jung HC. Upregulation of vanilloid receptor-1 in functional dyspepsia with or without Helicobacter pylori infection. Medicine (Baltimore). 2016;95(19):e3410.

95. Isomoto H, Saenko VA, Kanazawa Y, et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-b in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol. 2004;99(4):589-597.

96. Isomoto H, Wang A, Mizuta Y, et al. Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am J Gastroenterol. 2003;98(3):551-556.

97. Isomoto H, Wang A, Nishi Y, et al. Interleukin 8 and 1beta and RANTES levels in esophageal mucosa predict recurrence of endoscopy-negative gastroesophageal reflux disease. Hepatogastroenterology. 2008;55(82-83):482-485.

98. Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. The effect of emotional stress and depression on the prevalence of digestive diseases. J Neurogastroenterol Motil. 2015;21(2):273-282.

99. Fass R, Naliboff BD, Fass SS, et al. The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology. 2008;134(3):696-705.

100. Dean BB, Aguilar D, Johnson LF, et al. Night-time and daytime atypical manifestations of gastro-oesophageal reflux disease: frequency, severity and impact on health-related quality of life. Aliment Pharmacol Ther. 2008;27(4):327-337.

101. Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther. 2007;25(4):487-500.

102. Rao SS, Gregersen H, Hayek B, Summers RW, Christensen J. Unexplained chest pain: the hypersensitive, hyperreactive, and poorly compliant esophagus. Ann Intern Med. 1996;124(11):950-958.

103. Yoshida N, Kuroda M, Suzuki T, et al. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig Dis Sci. 2013;58(8):2237-2243.

104. Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue M. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut. 2001;48(5):630-636.

105. Keung C, Hebbard G. The management of gastro-oesophageal reflux disease. Aust Prescr. 2016;39(1):6-10.

106. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1392-1413.

107. Shaheen NJ, Weinber DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Int Med. 2012;157(11):808-816.

108. Muthusamy VR, Lightdale JR, Acosta RD, et al.; ASGE Standards of Practice Committee. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81(6):1305-1310.

109. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190-200.

110. Boeckxstaens G, El-Serag HB, Smout AJPM, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185-1193.

111. Riehl ME, Kinsinger S, Kahrilas PJ, Pandolfino JE, Keefer L. Role of a health psychologist in the management of functional esophageal complaints. Dis Esophagus. 2015;28(5):428-436.

112. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors. Can Fam Physician. 2017;63(5):354-364.

113. Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric junction opening during relaxation distinguishes non-hernia reflux patients, hernia patients, and normal subjects. Gastroenterology. 2005;125(4):1018-1024.

114. Hussain ZH, Henderson EE, Maradey-Romerao C, George N, Fass R, Lacy BE. The proton pump inhibitor non-responder: a clinical conundrum. Clin Transl Gastroenterol. 2015;6:e106.

115. American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81(6):1305-1310.

116. National Institute of Diabetes and Digestive and Kidney Diseases. Acid Reflux (GER & GERD) in Adults. Available at https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults/all-content. Last accessed September 7, 2021.

117. Trudgill NJ, Sifrim D, Sweis R, et al. British Society of Gastroenterology guidelines for oesophageal manometry and oesophageal reflux monitoring. Gut. 2019;68(10):1731-1750.

118. Capovilla G, Salvador R, Spadotto L, et al. Long-term wireless pH monitoring of the distal esophagus: prolonging the test beyond 48 hours is unnecessary and may be misleading. Dis Esophagus. 2017;30(10):1-8.

119. Martinucci I, de Bortoli N, Giacchino M, et al. Esophageal motility abnormalities in gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5(2):86-96.

120. Izawa S, Funaki Y, Iida A, et al. The role of gastroesophageal reflux in relation to symptom onset in patients with proton pump inhibitor-refractory nonerosive reflux disease accompanied by an underlying esophageal motor disorder. Digestion. 2014;89(1):61-67.

121. Dickman R, Boaz M, Aizic S, Beniashvili Z, Fass R, Niv Y. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17(4):387-389.

122. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastro-esophageal reflux disease. Am J Gastroenterol. 2011;106(8):1419-1425.

123. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295-309.

124. Bredenoord AJ. Management of belching, hiccups, and aerophagia. Clin Gastroenterol Hepatol. 2013;11(1):6-12.

125. Hemmink GJ, Ten Cate L, Bredenoord AJ, Timmer R, Weusten BL, Smout AJ. Speech therapy in patients with excessive supragastric belching: a pilot study. Neurogastroenterol Motil. 2010;22(1):24-28.

126. ROME Foundation. Appendix A: Rome IV Diagnostic Criteria for FGIDs: Esophageal Disorders. Available at https://theromefoundation.org/rome-iv/rome-iv-criteria/. Last accessed September 7, 2021.

127. Patel A, Sayuk GS, Gyawali CP. Parameters on esophageal pH-impedance monitoring that predict outcomes of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2015;13(5):884-891.

128. Galmiche JP, Clouse RE, Balint A, et al. Functional esophageal disorders. Gastroenterology. 2006;130(5):1459-1465.

129. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679-692.

130. Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc. 2009;69(4):917-930.

131. Fox M, Sweis R. Future directions in esophageal motility and function: new technology and methodology. Neurogastroenterol Motil. 2012;24(Suppl 1):48-56.

132. van Westen D, Ekberg O. Solid bolus swallowing in the radiologic evaluation of dysphagia. Acta Radiol. 1993;34(4):372-375.

133. Shaker A, Stoikes N, Drapekin J, Kushnir V, Brunt LM, Gyawali CP. Multiple rapid swallow responses during esophageal high-resolution manometry reflect esophageal body peristaltic reserve. Am J Gastroenterol. 2013;108(11):1706-1712.

134. Molina-Infante J, Gonzalez-Cordero PL, Lucendo AJ. Proton pump inhibitor-responsive esophageal eosinophilia: still a valid diagnosis? Curr Opin Gastroenterol. 2017;33(4):285-292.

135. Roman S, Zerbib F, Belhocine K, des Varannes SB, Mion F. High-resolution manometry to detect transient lower oesophageal sphincter relaxations: diagnostic accuracy compared with perfused-sleeve manometry, and the definition of new detection criteria. Aliment Pharmacol Ther. 2011;34(3):384-393.

136. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5(3):335-358.

137. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022-1033.e10.

138. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol. 2016;111(1):30-50.

139. Lowes H, Somarathna T, Shepherd NA. Definition, derivation, and diagnosis of Barrett's esophagus: pathological perspectives.Adv Exp Med Biol. 2016;908:111-136.

140. Iwakiri K. Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease, 2015.J Gastroenterol. 2016;51(8):751-767.

141. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380-1392.

142. Vakil N, Halling K, Ohlsson L, Wernersson B. Symptom overlap between post-prandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol. 2013;108(5):767-774.

143. Park HJ, Park S-H, Shim K-N, et al. The prevalence and clinical features of non-responsive gastroesophageal reflux disease to practical proton pump inhibitor dose in Korea: a multicenter study. Korean J Gastroenterol. 2016;68(1):16-22.

144. Rosmolen WD, Nieuwkerk PT, Pouw RE, van Berge Henegouwen MI, Bergman JJ, Sparnagers MA. Quality of life and fear of cancer recurrence after endoscopic treatment for early Barrett's neoplasia: a prospective study. Dis Esophagus. 2017;30(3):1-9.

145. Sethi S, Richter JE. Diet and gastroesophageal reflux disease: role in pathogenesis and management. Curr Opin Gastroenterol. 2017;33(2):107-111.

146. Ness-Jensen E, Hveem K, El-Serag P, et al. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14(2):175-182.

147. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(7):842-844.

148. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study. The HUNT study. Am J Gastroenterol. 2014;109(2):171-177.

149. El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut. 2005;54(1):11-17.

150. Eherer A. Management of gastroesophageal reflux disease: lifestyle modification and alternative approaches. Dig Dis. 2014;32(1-2):149-151.

151. Kubo A, Block G, Quesenberry CP Jr, Buffler P, Corley DA. Dietary guideline adherence for gastroesophageal reflux disease. BMC Gastroenterol. 2014;14:144.

152. Kang JH, Kang JY. Lifestyle measures in the management of gastro-oesophageal reflux disease: clinical and pathophysiological considerations. Ther Adv Chronic Dis. 2015;6(2):51-64.

153. Mardhiyah R, Makmun D, Syam AF, Setiati S. The effects of Ramadhan fasting on clinical symptoms in patients with gastroesophageal reflux disease. Acta Med Indones. 2016;48(3):169-174.

154. Fox RK, Muniraj T. Pharmacologic therapies in gastrointestinal diseases. Med Clin N Am. 2016;100(4):827-850.

155. Lexicomp Online. Available at https://online.lexi.com. Last accessed September 7, 2021.

156. Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30(9):1-15.

157. Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med. 2017;15:36.

158. Vaezi MF, Yang Y-X, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35-48.

159. NCBI. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Proton Pump Inhibitors. Available at https://www.ncbi.nlm.nih.gov/books/NBK547892. Last accessed September 7, 2021.

160. Savarino V, Pace F, Scarpignato C, Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease-efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631-642.

161. Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302-318.

162. Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61(9):1340-1354.

163. Hillman L, Yadlapati R, Whitsett M, Thuluvath AJ, Berendsen MA, Pandolfino JE. Review of antireflux procedures for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30(9):1-14.

164. Zhang C, Kwong JSW, Yuan R-X, et al. Effectiveness and tolerability of different recommended doses of PPIs and H2RAs in GERD: network meta-analysis and GRADE system. Sci Rep. 2017;7:41021.

165. Labenz J, Armstrong D, Leodolter A, Baldycheva I. Management of reflux esophagitis: does the choice of proton pump inhibitor matter? Int J Clin Pract. 2015;69(7):796-801.

166. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.

167. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24(8):747-757.

168. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors: comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19-31.

169. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011;9(10):824-833.

170. McCallum RW, Zarling EJ, Goetsch AC, et al. Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease. Am J Med Sci. 2010;340(4):259-263.

171. Fock KM, Poh CH. Gastroesophageal reflux disease. J Gastroenterol. 2010;45(8):808-815.

172. Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31(6):625-630.

173. de Bortoli N, Guidi G, Martinucci I, et al. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. Dis Esophagus. 2016;29(2):197-204.

174. Pollock K, Grime J. The cost and cost-effectiveness of PPIs: GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centered healthcare. Eur J Gen Pract. 2003;9(4):126-133, 140.

175. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80-87.

176. Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116(2):239-247.

177. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric secretion. Aliment Pharmacol Ther. 2005;21(2):149-154.

178. Lee C, Lo A, Ubhi K, Milewski M. Outcome after discontinuation of proton pump inhibitors at a residential care site: quality improvement project. Can J Hosp Pharm. 2017;70(3):215-223.

179. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42. di Pietro M, Fitzgerald RC, on behalf of the BSG Barrett's guidelines working group. Gut. 2017;0:1-2.

180. Singh S, Garg SK, Singh PP, Iyer PG, El-Seraq HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8):1229-1237.

181. Akiyama J, Bertele A, Brock C, et al. Benign and precursor lesions in the esophagus. Ann N Y Acad Sci. 2014;1325:226-241.

182. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314(17):1818-1831.

183. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747-748.

184. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735.

185. Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273-297.

186. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-2246.

187. Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus. Drugs. 2017;77(5):547-561.

188. Storr MA. What is nonacid reflux disease? Can J Gastroenterol. 2011;25(1):35-38.

189. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370-373.

190. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676-679.

191. Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014;20(1):6-16.

192. Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20(9):2412-2419.

193. Tack J, Zerbib F, Blondeau K, et al. Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment. Neurogastroenterol Motil. 2015;27(2):258-268.

194. Shaheen NJ, Adler J, Dedrie S, et al. Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy. Aliment Pharmacol Ther. 2015;41(7):649-661.

195. Lei WY, Hung JS, Liu TT, Yi CH, Chen CL. Influence of prucalopride on esophageal secondary peristalsis in reflux patients with ineffective motility. J Gastroenterol Hepatol. 2018;33(3):650-655.

196. Abbasinazari M, Panahi Y, Mortazavi SA, et al. Effect of a combination of omeprazole plus sustained release baclofen versus omeprazole alone on symptoms of patients with gastroesophageal reflux disease (GERD). Iran J Pharm Res. 2014;13(4):1221-1226.

197. Surdea-Blaga T, Băncilă I, Dobru D, et al. Mucosal protective compounds in the treatment of gastroesophageal reflux disease: a position paper based on evidence of the Romanian Society of Neurogastroenterology. J Gastrointestin Liver Dis. 2016;25(4):537-546.

198. Coyle C, Crawford G, Wilkinson J, Thomas SJ, Bytzer P. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther. 2017;45(12):1524-1533.

199. Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1-9.

200. Reimer C, Lødrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899-909.

201. Candelli M, Carloni E, Armuzzi A, et al. Role of sucralfate in gastrointestinal diseases. Panminerva Med. 2000;42(1):55-59.

202. Palmieri B, Merighi A, Corbascio D, Rottigni V, Fistetto G, Esposito A. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur Rev Med Pharmacol Sci. 2013;17(24):3272-3278.

203. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17(2):110-123.

204. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut. 2008;57(5):674-683.

205. Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2012;107(11):1662-1667.

206. Forcelini CM, Tomiozzo JC Jr, Farré R, et al. Effect of nortriptyline on brain responses to painful esophageal acid infusion in patients with non-erosive reflux disease. Neurogastroenterol Motil. 2014;26(2):187-195.

207. Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2015;13(2):251-259.

208. Keefer L, Kahrilas PJ. Low-dose tricyclics for esophageal hypersensitivity: is it all placebo effect? Am J Gastroenterol. 2016;111(2):225-227.

209. Nguyen TM, Eslick GD. Systematic review: the treatment of noncardiac chest pain with antidepressants. Aliment Pharmacol Ther. 2012;35(5):493-500.

210. Jha LK, Fass R, Gadam R, et al. The effect of ramelteon on heartburn symptoms of patients with gastroesophageal reflux disease and chronic insomnia: a pilot study. J Clin Gastroenterol. 2016;50(2):e19-e24.

211. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23(10):1473-1477.

212. Richter JE. Current diagnosis and management of suspected reflux symptoms refractory to proton pump inhibitor therapy. Gastroenterol Hepatol. 2014;10(9):547-555.

213. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GERD: an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135-153.

214. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis: a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36(7):635-643.

215. Kethman W, Hawn M. New approaches to gastroesophageal reflux disease. J Gastrointest Surg. 2017;21(19):1544-1552.

216. Asti E, Bonitta G, Lovece A, Lazzari V, Bonavina L. Longitudinal comparison of quality in patients undergoing Toupet fundoplication versus magnetic sphincter augmentation. Medicine (Baltimore). 2016;95(30):1-6.

217. Kim D, Velanovich V. Surgical treatment of GERD: where have we been and where are we going? Gastroenterol Clin North Am. 2014;43(1):135-145.

218. Lundell L, Bell M, Ruth M. Systematic review: laparoscopic fundoplication for gastroesophageal reflux disease in partial responders to proton pump inhibitors. World J Gastroenterol. 2014;20(3):804-813.

219. Broeders JA, Draaisma WA, Bredenoord AJ, Smout AJ, Broeders IA, Gooszen HG. Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux disease. Br J Surg. 2010;97(6):845-852.

220. Broeders JA, Rijnhart-de Jong HG, Draaisma WA, Bredenoord AJ, Smout AJ, Gooszen HG. Ten-year outcome of laparoscopic and conventional Nissen fundoplication: randomized clinical trial. Ann Surg. 2009;250(5):698-706.

221. Kelly JJ, Watson DI, Chin KF, Devitt PG, Game PA, Jamieson GG. Laparoscopic Nissen fundoplication: clinical outcomes at 10 years. J Am Coll Surg. 2007;205(4):570-575.

222. Lødrup A, Pottegard A, Hallas J, Bytzer P. Use of proton pump inhibitors after anti-reflux surgery: a nationwide register-based follow-up study. Gut. 2014;63(10):1544-1549.

223. Rosenthal R, Peterli R, Guenin MO, von Flüe M, Achermann C. Laparoscopic antireflux surgery: long-term outcomes and quality of life. J Laparoendosc Adv Surg Tech A. 2006;16(6):557-561.

224. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3(3):292-300.

225. Ganz RA. A review of new surgical and endoscopic therapies for gastroesophageal reflux disease. Gastroenterol Hepatol. 2016;12(7):424-431.

226. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7(12):1292-1298.

227. Wang YR, Dempsey DT, Richter JE. Trends and perioperative outcomes of inpatient antireflux surgery in the United States, 1993–2006. Dis Esophagus. 2011;24(4):215-223.

228. Smith CD, Ganz RA, Lipham JC, Bell RC, Rattner DW. Lower esophageal sphincter augmentation for gastroesophageal reflux disease: the safety of a modern implant. J Laparoendosc Adv Surg Tech A. 2017;27(6):586-591.

229. Ganz RA. A modern magnetic implant for gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2017;15(9):1326-1337.

230. Warren HF, Brown LM, Mihura M, Farivar AS, Aye RW, Louie BE. Factors influencing the outcome of magnetic sphincter augmentation for chronic gastroesophageal reflux disease. Surg Endosc. 2018;32(1):405-412.

231. Richter JE, Kumar A, Lipka S, Miladinovic B, Velanovich V. Efficacy of laparoscopic Nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis. Gastroenterology. 2018;154(5):1298-1308.

232. Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(6):1058-1067.

233. Lundell L. Borderline indications and selection of gastroesophageal reflux disease patients: "Is surgery better than medical therapy?" Dig Dis. 2014;32(1-2):152-155.

234. Varela JE, Hinojosa MW, Nguyen NT. Laparoscopic fundoplication compared with laparoscopic gastric bypass in morbidly obese patients with gastroesophageal reflux disease. Surg Obes Relat Dis. 2009;5(2):139-143.

235. Kavanagh R, Smith J, Bashir U, Jones D, Avgenakis E, Nau P. Optimizing bariatric surgery outcomes: a novel preoperative protocol in a bariatric population with gastroesophageal reflux disease. Surg Endosc. 2020; 34(4):1812-1818.

Evidence-Based Practice Recommendations Citations

1. University of Michigan. Guidelines for Clinical Care: Gastroesophageal Reflux Disease (GERD). Available at https://www.med.umich.edu/1info/FHP/practiceguides/gerd/gerd.12.pdf. Last accessed September 17, 2021.

2. ASGE Standards of Practice Committee, Muthusamy VR, Lightdale JR, et al. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81(6):1305-1310. Available at https://www.asge.org/docs/default-source/education/practice_guidelines/doc-endoscopy_in_the_managment_of_gerd.pdf. Last accessed September 17, 2021.

3. Stefanidis D, Richardson W, Dunkin B. Clinical Spotlight Review: Endoluminal Treatments for Gastroesophageal Reflux Disease (GERD). Available at https://www.sages.org/publications/guidelines/endoluminal-treatments-for-gastroesophageal-reflux-disease-gerd. Last accessed September 17, 2021.



Privacy Policy
Copyright © 2021 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.